02373nas a2200241   4500000000100000008004100001260001200042653001600054653005600070653002300126653001200149653001700161100001300178700001200191700001700203700001700220245006800237856009000305300000800395490000700403520170700410022001402117       2023                            d  c08/202310aCoinfection10aglucose-6-phosphate-dehydrogenase deficiency (g6pd)10aHansen’s disease10aleprosy10aTuberculosis1 aHansen P1 aMyers E1 aRajalingam K1 aLabanowski M00aA Rare Case of Hansen's Disease Complicated by G6PD Deficiency.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471196/pdf/cureus-0015-00000042816.pdf  a1-50 v153 a<p>We present the case of a 37-year-old Haitian male who presented with a seven-month history of skin lesions on his face and extremities, weight loss, intermittent chills, difficulty in breathing, and bilateral paresthesias in his feet. The lesions were most prominent on the pinnae of the ears. Biopsy of the lesions revealed large, rounded granulomatous infiltrates and histiocytes. Acid fast (Ziehl-Neelsen technique) and Kinyoun stains were positive for numerous acid-fast mycobacteria within the histiocytes. A polymerase chain reaction (PCR) was positive for which confirmed a diagnosis of lepromatous leprosy. Further analysis revealed positive purified protein derivatives (PPD) and QuantiFERON-TB™ test (QIAGEN, Hilden, Germany) with negative chest x-ray and sputum cultures. Labs also revealed vitamin D and G6PD (glucose-6-phosphate-dehydrogenasedeficiency. The patient was started on a combined therapy regimen of rifampin, moxifloxacin, and minocycline. In addition, he was started on vitamin D supplementation. After undergoing treatment for one year, there was notable regression of the patient's cutaneous lesions. Treatment is planned to continue for a total of 24 months. This case exemplifies the successful treatment of Hansen's disease in a patient with a G6PD deficiency. The patient's G6PD deficiency required avoidance of dapsone, which is typically used in the treatment of Hansen's disease. Furthermore, the patient's positive PPD and QuantiFERON-TB tests led to a delay in the treatment in order to rule out active tuberculosis. Left untreated, Hansen's disease has a high morbidity risk. Treatment regimens require careful consideration of coexisting comorbidities.</p>
  a2168-8184